Domača stranATHA • NASDAQ
add
Athira Pharma Inc
Prejšnji trg. dan.
0,59 $
Dnevni razpon
0,56 $ - 0,60 $
Letni razpon
0,41 $ - 4,30 $
Tržna kapitalizacija
21,74 mio. USD
Povprečni obseg
305,48 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | — | — |
Stroški poslovanja | 25,49 mio. | −27,25 % |
Čisti dohodek | −28,74 mio. | 12,83 % |
Čista dobičkovnost prihodkov | — | — |
Earnings per share | — | — |
EBITDA | −25,25 mio. | 27,44 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 68,86 mio. | −60,19 % |
Skupna sredstva | 86,25 mio. | −53,30 % |
Skupne obveznosti | 28,66 mio. | −4,25 % |
Celoten lastniški kapital | 57,58 mio. | — |
Shares outstanding | 38,67 mio. | — |
Razmerje P/B | 0,40 | — |
Donosnost sredstev | −64,54 % | — |
Donosnost kapitala | −88,74 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −28,74 mio. | 12,83 % |
Denar iz dejavnosti | −23,02 mio. | 4,01 % |
Denar iz naložb | 18,04 mio. | −12,81 % |
Denar iz financiranja | 12,00 tis. | — |
Neto sprememba denarnih sredstev | −4,97 mio. | −50,94 % |
Prost denarni tok | −10,13 mio. | 13,86 % |
Vizitka
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Datum ustanovitve
2011
Sedež organizacije
Spletno mesto
Zaposleni
66
